株探米国株
英語
エドガーで原本を確認する
6-K 1 form6-k.htm REPORT OF FOREIGN PRIVATE ISSUER

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
 
October 14, 2025
 
Commission File Number: 001-38159

 
BRITISH AMERICAN TOBACCO P.L.C.
(Translation of registrant’s name into English)

 
Globe House
4 Temple Place
London WC2R 2PG
United Kingdom
(Address of principal executive office)

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒              Form 40-F ☐
 
 
 
 

 
This report includes materials as exhibits that have been published and made available by British American Tobacco p.l.c. (the “Registrant”) as of October 14, 2025.

The information contained in Exhibit 1 to this Form 6-K is incorporated by reference into the Form S-8 Registration Statements File Nos. 333-223678, 333-219440, 333-237186, 333-285085 and 333-289164 of the Registrant and into the Form F-3 Registration Statement File Nos. 333-288448, 333-288448-01, 333-288448-02, 333-288448-03, 333-288448-04 and 333-288448-05 of the Registrant, British American Tobacco Holdings (The Netherlands) B.V., B.A.T. Capital Corporation, B.A.T. Netherlands Finance B.V., Reynolds American Inc. and B.A.T. International Finance p.l.c., and related Prospectuses, as such Registration Statements and Prospectuses may be amended from time to time.

EXHIBIT INDEX
 
Exhibit
 
Description
  
 
 
Exhibit 1
 

  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
British American Tobacco p.l.c.
  
   
 
       
 
By:
/s/ Christopher Worlock
  
    Name: 
Christopher Worlock  
    Title:   
Assistant Secretary
  
       
 
Date:  October 14, 2025
EX-1 2 ex-1.htm PRESS RELEASE
Exhibit 1

British American Tobacco p.l.c. (the “Company” or “BAT”)

14 October 2025 

Board Change

Matthew Wright will join the Board of British American Tobacco p.l.c. as an independent Non-Executive Director with effect from 1 November 2025 and will be appointed as a member of the Remuneration and Nominations Committees.

Matt has spent his career advising leading organisations on the recruitment, retention and development of senior talent to support transformation and growth. Between 1993 and 2013, Matt held roles at Russell Reynolds Associates including the role of Chief Executive, President and Member of the Board, Head of Asia and Europe, Member of the Global Executive Committee and Member of the Global Operating Committee. Prior to that Matt held various roles at Korn/Ferry International, Knight Wendling and Cripps Leadership Advisors (formerly Cripps Sears Ltd).

Commenting on the appointment, Luc Jobin, Chair of the Board, said: “I am pleased to welcome Matt Wright to our Board. Cultural transformation is critical to our sustainable future, and having laid the foundations, we are progressing well.  Matt brings valuable experience in this area. He also brings extensive international experience across Asia, Europe and the US, having led and advised global organisations in different sectors through periods of growth and transformation. His proven leadership and strong people acumen will be valuable assets as BAT continues on its ambition to build a Smokeless World.”

Matt currently serves as Non-Executive Director of Berry Bros. & Rudd Ltd, where he also chairs the Remuneration Committee, Chairman of Cripps Leadership Advisors and Chair Designate and Senior Advisor of Movemeon.


Enquiries:

Media Centre
press_office@bat.com | @BATplc

Investor Relations
Victoria Buxton | IR_team@bat.com

Additional information

1.  This announcement is made in compliance with the Company’s obligations under UKLR 6.4.6.

2.  In accordance with the Listing Rules, Matthew Wright has not been a director of any publicly quoted companies in the previous five years.

There are no additional matters that would require disclosure under UKLR 6.4.8 in respect of this appointment.